繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 心血管系统 >> 新药动态 >> Abciximab(阿昔单抗:ReoPro)

Abciximab(阿昔单抗:ReoPro)

2010-06-29 22:24:14  作者:新特药房  来源:互联网  浏览次数:936  文字大小:【】【】【
简介: 适应症 参见用法用量。 适应症/成人常用量 静脉给药 不稳定型心绞痛;经皮冠脉介入 (PCI)治疗期间辅助用药预防急性缺血发作 250 mcg/kg,静脉小壶,然后以0.125 mcg/kg/分的速率滴注(最大:10 mcg ...

 适应症 
 参见用法用量。
适应症/成人常用量 
 静脉给药 不稳定型心绞痛;经皮冠脉介入 (PCI)治疗期间辅助用药预防急性缺血发作 250 mcg/kg,静脉小壶,然后以0.125 mcg/kg/分的速率滴注(最大:10 mcg/分)。不稳定型心绞痛:最早在PCI前24小时开始滴注至手术后12小时。预防PCI急性缺乏并发症:PCI前 10-60分钟开始滴注,直至手术后12小时。
点击查看不同适应症和各年龄组别患者的用法用量
禁忌 
 以下情况禁用:对本药任何成份或鼠类蛋白质过敏,活动性出血,近期(6周以内)胃肠道出血或有临床意义的泌尿生殖系出血,2年内脑血管意外或遗留明显神经系统缺陷,出血体质,血小板减少症(<10000/uL),凝血功能异常,1周内曾使用口服抗凝药,近期(6周)外科大手术或创伤,颅内肿瘤,动静脉畸形或动脉瘤,严重未控制的高血压,重度肝肾功能损害,可疑或明确的脉管炎病史,PTCA术前或术中需静脉注射右旋糖苷。
注意事项 
 以下情况慎用:75岁以上的老人,妊娠和哺乳期妇女、18岁以下儿童,体重低于75 kg,近期溶栓治疗和经皮冠状动脉成形术未成功的患者。再次给药,合用溶栓药、抗凝药和其它抗血小板药物,静脉开放和/或动静脉穿刺/插管的患者。给药前,检查血小板计数、凝血酶原时间和活化部分凝血活酶时间,明确是否存在凝血异常。
不良反应 
 低血压、心动过缓、胸骨后或胸痛、心房颤动/扑动、恶心、呕吐、头痛、发热、血肿、血管疾病、贫血、白细胞增多、感觉迟钝、精神混乱、思维异常、头晕、胸膜炎、胸腔渗液、肺炎、尿路感染、疼痛、周围水肿、视力异常、发音困难、瘙痒症、溶血性贫血、皮肤淤斑。
严重不良反应: 出血(给药后首3个小时,如胃肠道、泌尿生殖道、腹膜后)、血小板减少、产生抗人嵌合抗体。
药物相互作用 
 人抗嵌合抗体(HACA)阳性的患者如使用其它诊断性或治疗性单克隆抗体,可能出现过敏或超敏反应。
严重药物相互作用: 合用溶栓药、抗凝药和其它抗血小板药,增加出血的风险。
查看 详细药物相互作用 

FDA妊娠分级
     
C级: 动物研究证明药物对胎儿有危害性(致畸或胚胎死亡等),或尚无设对照的妊娠妇女研究,或尚未对妊娠妇女及动物进行研究。本类药物只有在权衡对孕妇的益处大于对胎儿的危害之后,方可使用。 
 
法国研究者报告,对急性ST段抬高的心肌梗死(STEMI)患者的长期随访显示,进行支架置入同时接受GPIIb/IIIa受体抑制剂阿昔单抗(abciximab )的患者比只接受支架置入的患者有较高的生存率。

Pitie-Salpetriere大学医院的Gilles Montalescot医生说,药物的初始益处在3年的随访中持续存在。先前的研究只对患者随访了30天。在12月的《欧洲心脏杂志》(Eur Heart J 2005; 26:2520-2523)上,Montalescot医生及其同事指出,本研究继续随访接受了阿昔单抗以及支架置入的149例STEMI患者。另外151例患者接受安慰剂和支架置入。

对288例患者盲随访3年并使用意向-治疗分析显示,全因死亡率阿昔单抗组为9.1%,安慰剂组为12.2%。死亡或再梗死的累及发生率阿昔单抗组为11.8%,安慰剂组为16.9%。阿昔单抗组复发性缺血也显著减少(11.5% vs 21.7%)。

Montalescot医生总结说,使用基础血管成形术治疗的ST段抬高的心肌梗死是使用GPIIb/IIIa抑制剂的最佳临床指征。

 Brand names: ReoPro®

Abciximab Solution for injection

What is this medicine?

ABCIXIMAB (ab SIX i mab) prevents blood clots during episodes of chest pain or a heart attack. It may be used during heart surgery.
 
This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.

What should I tell my health care provider before I take this medicine?

They need to know if you have any of these conditions:
•bleeding problems or blood disorders
•brain tumor or aneurysm
•high blood pressure
•previous stroke
•recent injury or surgery
•took a drug to prevent blood clots like warfarin in the past week
•vasculitis
•an unusual or allergic reaction to abciximab, mouse or human proteins, other medicines, foods, dyes, or preservatives
•pregnant or trying to get pregnant
•breast-feeding

How should I use this medicine?

The medicine is for injection or infusion into a vein. It is given by a health care professional in a hospital or clinic setting.

Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.

Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.
NOTE: This medicine is only for you. Do not share this medicine with others.

What may interact with this medicine?

•aspirin and aspirin-like drugs
•clopidogrel
•dipyridamole
•herbal products containing feverfew, garlic, ginger, ginkgo, or horse chestnut
•medicines that break up blood clots like alteplase, reteplase, streptokinase, and urokinase
•medicines that treat or prevent blood clots like warfarin, enoxaparin, dalteparin, tinzaparin, argatroban, bivalirudin, and lepirudin
•NSAIDs, medicines for pain and inflammation, like ibuprofen or naproxen
•ticlopidine

This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.

What should I watch for while using this medicine?

Your condition will be monitored carefully while you are receiving this medicine.

What side effects may I notice from receiving this medicine?

Side effects that you should report to your doctor or health care professional as soon as possible:
•allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue
•breathing problems
•chest pain
•unusual bleeding or bruising

Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):
•back pain
•dizziness
•headache
•nausea
•stomach pain

This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Where should I keep my medicine?

This drug is given in a hospital or clinic and will not be stored at home.

Last updated: 7/1/2002

责任编辑:admin


相关文章
阿昔单抗注射剂|Reopro(Abciximab)
ReoPro®(Abciximab阿昔单抗)
阿昔单抗结合抗凝血药物可显著减少支架移植并发症
阿昔单抗可改善急性冠脉综合征患者的PCI结果
阿昔单抗注射剂(Abciximab, ReoPro,Clotinab)
 

最新文章

更多

· 新型口服抗凝血剂Lixian...
· 美国FDA批准Repatha注射...
· 降血脂新类型单抗药Repa...
· 美国FDA批准Praluent(al...
· 美国FDA批准Entresto为治...
· 慢性心衰创新药物Entres...
· 新型血小板药Kengreal(...
· 美国FDA批准第三代SAPIE...
· FDA批准Corlanor(ivabra...
· FDA批准Cholbam胶囊治疗...

推荐文章

更多

· 新型口服抗凝血剂Lixian...
· 美国FDA批准Repatha注射...
· 降血脂新类型单抗药Repa...
· 美国FDA批准Praluent(al...
· 美国FDA批准Entresto为治...
· 慢性心衰创新药物Entres...
· 新型血小板药Kengreal(...
· 美国FDA批准第三代SAPIE...
· FDA批准Corlanor(ivabra...
· FDA批准Cholbam胶囊治疗...

热点文章

更多

· 美国FDA批准Repatha注射...
· 新型口服抗凝血剂Lixian...